Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Treatment of Peri-calcification Edema in Neurocysticercosis (NCC)
NCT02945527 · Universidad Peruana Cayetano Heredia · PHASE2/PHASE3 · terminated · last registry update 2025-04-01 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low recruitment” | – | Registry record, Universidad Peruana Cayetano Heredia |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-13Phase 3 first posted: Hospital de Clinicas de Porto Alegre, Furosemide 40 Milligrams. + Furosemide 40 Milligrams. (NCT07469722)
- 2026-01-28Results posted on the registry: Medical College of Wisconsin, Patient-controlled analgesia (PCA) (NCT05144828)
- 2025-12-22Phase 3 first posted: University of California, San Francisco, Pharmacologic Pain Management (NCT07296770)
- 2025-09-24Also stopped (terminated): AstraZeneca, AZD5462 + Dapagliflozin (NCT06639087)
- 2025-08-26Results posted on the registry: University of Miami, Latanoprost + Bimatoprost (NCT02390284)
- 2025-08-26Also stopped (terminated): University of Miami, Latanoprost + Bimatoprost (NCT02390284)
- 2025-08-08Results posted on the registry: Vrije Universiteit Brussel, Intravenous acetazolamide 500 mg OD + Intravenous bumetanide TID (NCT05411991)
- 2025-03-20Results posted on the registry: Mayo Clinic, Placebo + Acetazolamide (NCT04679389)
- 2025-03-20Also stopped (terminated): Mayo Clinic, Placebo + Acetazolamide (NCT04679389)
- 2025-02-14Also stopped (terminated): Stadtspital Zürich, Furosemide + Metolazone (NCT05986773)
- 2025-01-31Also stopped (terminated): Aziende Chimiche Riunite Angelini Francesco S.p.A, 380 mg/300 mg comprimidos metocarbamol/paracetamol - 4 times daily + 380 mg/300 mg comprimidos metocarbamol/paracetamol - 6 times daily (NCT05204667)
- 2025-01-20Phase 3 first posted: Mansoura University, Dapagliflozin 10mg + Acetazolamide 500mg (NCT06783166)
- 2024-10-28Results posted on the registry: Ziekenhuis Oost-Limburg, Acetazolamide + Placebo (NCT03505788)
- 2024-09-25Also stopped (withdrawn): Henry Ford Health System, Acamprosate + Placebo (NCT06312800)
- 2024-08-19Phase 3 first posted: Campbell Clinic, Opiate Sparing + Opiate Based (NCT06561035)
- 2024-08-02Phase 3 first posted: Helwan University, Acetazolamide + Dapagliflozin 10mg (NCT06535529)
- 2024-05-02Results posted on the registry: University of California, San Diego, Acetazolamide + Eszopiclone (NCT04639193)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision